Search by CAS No , Chemical Name or Molecular Formula
"Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used for the treatment of hepatitis C. It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir, or daclatasvir. Cure rates are 30 to 97% depending on the type of hepatitis C virus involved. Safety during pregnancy is unclear; while, some of the medications used in combination may result in harm to the baby. It is taken by mouth.
Common side effects include feeling tired, headache, nausea, and trouble sleeping. Side effects are generally more common in interferon-containing regimens. Sofosbuvir may reactivate hepatitis B in those who have been previously infected. In combination with ledipasvir, daclatasvir or simeprevir it is not recommended with amiodarone due to the risk of an abnormally slow heartbeat. Sofosbuvir is in the nucleotide analog family of medication and works by blocking the hepatitis C NS5B protein.
Sofosbuvir was discovered in 2007 and approved for medical use in the United States in 2013. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. As of 2016 a 12-week course of treatment costs about $84,000 in the United States, $53,000 in the United Kingdom, $45,000 in Canada, and $483 in India. Over 60,000 people were treated with sofosbuvir in its first 30 weeks being sold in the United States.",""
Sofosbuvir Stable Isotope;Labeled Sofosbuvir, intended for use as an internal standard for the quantification of Sofosbuvir by GC- or LC-mass spectrometry.
Divya Rajagopal for the Economic Times. Sept 12, 2015;Tran TT (December 2012).
We normally respond within 8 hours.
This page contains information about Sofosbuvir 13CD3 Cas # 2070009-25-3 and its Stable Isotopes.
Sofosbuvir 13CD3 Sofosbuvir 13CD3 Worldwide Suppliers of Sofosbuvir 13CD3 https://www.clearsynth.com/en/CSO30474.html Stable Isotopes Clearsynth 2070009-25-3
Regular price: $2400 In stock
Product rating: 9 Sofosbuvir 13CD3 based on 20 ratings
Keywords: Sofosbuvir 13CD3, CS-O-30474, 2070009-25-3, , C21[1C]H26D3FN3O9P, 533.46, Sofosbuvir Stable Isotope;Labeled Sofosbuvir, intended for use as an internal standard for the quantification of Sofosbuvir by GC- or LC-mass spectrometry.
Internal standard, Internal standard Sofosbuvir, HPLC-MS method validation, HPLC-MS method validation Sofosbuvir, LC-MS-MS method validation, LC-MS-MS method validation Sofosbuvir, Deuterated internal standard, Deuterated internal standard Sofosbuvir, Deuterated Sofosbuvir, Deuterium labeled Sofosbuvir, Quantitative bioanalytical methods, Quantitative bioanalytical methods Sofosbuvir, Blood samples Sofosbuvir, Blood concentrations, Heavy drugs, Analysis, Analysis Sofosbuvir, Clinical diagnostic, Clinical diagnostic Sofosbuvir, Dosing Sofosbuvir, Analytical method development, Internal standard method.
CLEARSYNTH CANADA INC.
2395 Speakman Drive,
Lab: 1001, Mississauga, ON,
Canada L5K 1B3
T : +1-289-729-0060
CLEARSYNTH RESEARCH CENTRE
Plot No. 177, IDA, Mallapur,
T : +91-40-27155481
CLEARSYNTH LABS LTD
17, Lotus Business Park,
Andheri (W), Mumbai - 400053
T : +91-22-45045945